Focused On-demand Library for Polycomb protein SUZ12

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q15022

UPID:

SUZ12_HUMAN

Alternative names:

Chromatin precipitated E2F target 9 protein; Joined to JAZF1 protein; Suppressor of zeste 12 protein homolog

Alternative UPACC:

Q15022; Q96BD9

Background:

Polycomb protein SUZ12, known as Chromatin precipitated E2F target 9 protein, Joined to JAZF1 protein, and Suppressor of zeste 12 protein homolog, plays a pivotal role in gene silencing. As a core component of the PRC2 complex, it methylates histone H3 on Lys-9 and Lys-27, leading to transcriptional repression of genes like HOXC8, HOXA9, MYT1, and CDKN2A.

Therapeutic significance:

The involvement of SUZ12 in Imagawa-Matsumoto syndrome, characterized by overgrowth, dysmorphic features, and intellectual disability, underscores its potential as a target for therapeutic intervention. Understanding the role of Polycomb protein SUZ12 could open doors to potential therapeutic strategies.